Thermo Fisher Scientific Reports 6% Q1 2026 Revenue Growth, Raises Full-Year Guidance
Thermo Fisher Scientific Inc. reported 6% revenue growth in Q1 2026, driven by bioproduction and clinical research, despite declines in academic and government sectors. The company raised full-year revenue guidance to $47.3–$48.1 billion and adjusted EPS to $24.64–$25.12, citing strong productivity and the Clario acquisition. Strategic collaborations and AI innovations were highlighted as key drivers.
Topics: Acquisition AI Biotech Clinical Research Earnings Revenue Growth Strategic Partnerships